Atrioventricular Dissociation after Electroconvulsive Therapy by Yu, Siegfried William et al.
SAGE-Hindawi Access to Research
Cardiology Research and Practice
Volume 2011, Article ID 746373, 4 pages
doi:10.4061/2011/746373
Case Report
Atrioventricular Dissociation after ElectroconvulsiveTherapy
SiegfriedWilliamYu,1 SrikanthVallurupalli,1 Jennifer Arnoldi,2 andRichardHolloway3
1Department of Internal Medicine, Southern Illinois University School of Medicine, Springﬁeld, IL 62711, USA
2School of Pharmacology, Southern Illinois University Edwardsville and St. John’s Hospital, Springﬁeld, IL 62711, USA
3Southern Illinois University School of Medicine and Prairie Cardiovascular Consultants, Springﬁeld, IL, USA
Correspondence should be addressed to Siegfried William Yu, syu2.siumed@gmail.com
Received 2 March 2011; Revised 15 July 2011; Accepted 16 July 2011
Academic Editor: Gavin W. Lambert
Copyright © 2011 Siegfried William Yu et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Electroconvulsive therapy (ECT) is increasingly used as a treatment for psychiatric disorders. Cardiac eﬀects are the principal
cause of medical complications in these patients. We report a case of atrioventricular (AV) dissociation that occurred after ECT
that was treated with pacemaker implantation. The mechanisms contributing to the onset of AV dissociation in this patient, and
the management and rationale for device therapy, in light of the most recent guidelines, are reviewed.
1.Introduction
Electroconvulsive therapy (ECT) has been used as a treat-
ment for psychiatric disorders since the 1930s. It is a very
useful treatment for severe depression that is being used
increasingly [1] and is considered the most eﬀective treat-
ment in psychiatry [2]. A number of large studies and meta-
analysesconﬁrmtheeﬃcacyandsafetyofECT.Cardiaccom-
plications are the principal cause of medical complications
related to ECT [3]. Although they are usually insigniﬁcant,
a small percentage of these cardiac complications can be
potentially fatal. We report a case of complete atrioventricu-
lar (AV) block that occurred after ECT, discuss the possible
mechanisms involved, and review the management of the
case.
2.CaseReport
A 65-year-old woman with type 1 bipolar disorder, hypothy-
roidism, hypertension, and hyperlipidemia was admitted to
the psychiatric unit with worsening depression and inability
to care for self at home. She had no documented history
of coronary artery disease or previous myocardial infarc-
tion. Her medications included risperidone, venlafaxine,
bupropion, aspirin, levothyroxine, simvastatin, lorazepam,
and gabapentin. Upon admission bupropion and gabapentin
were discontinued, and escitalopram and mirtazapine were
added. Because her depression was resistant to medical ther-
apy, ECT was pursued. Her baseline ECG (see Figure 1)
demonstrated sinus rhythm, with a right bundle branch
block (RBBB) pattern and Q waves in leads III and aVF
suggesting a previous inferior infarct. The PR interval was
normal at 160 milliseconds (ms). Hydrochlorothiazide and
amlodipine were prescribed for her untreated hypertension.
She was started on three sessions of unilateral ECT a
week, with a frequency of 60 hertz and a current of 800
milliamperes. Premedication for each ECT session consisted
of intravenous methohexital and succinylcholine. Intra-
venous labetalol was given as needed before and after the
ECT sessions for elevated blood pressure. She tolerated the
initial sessions well. Prior to her 5th ECT session, she was
started on oral metoprolol succinate at a dose of 25mg daily
for uncontrolled blood pressure. Her blood pressure re-
mained elevated, and the dose was increased to 50mg daily
prior to her 8th ECT session. The seizure duration during
her 8th ECT session was 238 seconds, which did not diﬀer
signiﬁcantly from the prior sessions (range 20–458 seconds).
Thirty minutes after her 8th ECT session, the patient was
noted to be bradycardic in the post-ECT monitoring area.
The patient was asymptomatic with a blood pressure of
120/80mmHg. A 12-lead ECG (see Figure 2) revealed an


























Figure 2: AV dissociation occurring after the 8th ECT session.
of60perminute,consistentwithAVdissociation,withaQRS
morphology resembling her preexisting RBBB and a QTc
interval of 416ms.
She was transferred to the coronary care unit, where the
rhythm persisted for approximately 6 hours before a repeat
12-leadECGconﬁrmedreturntosinusrhythm.Herthyroid-
stimulating hormone levels were within normal limits. A
transthoracicechocardiogramrevealedsevereleftventricular
(LV) hypertrophy, and an ejection fraction of 80% with near
obliteration of the left ventricular cavity on systole, creating
an LV outﬂow tract obstruction not aﬀected by valsalva ma-
neuver. The LV diastolic ﬁlling pattern was consistent with
impaired LV relaxation. Electrophysiological consultation
was obtained, and she underwent implantation of a dual-
chamber pacemaker. Regadenoson radionuclide stress imag-
ing was negative for cardiac ischemia. She underwent 3
subsequent ECT sessions without complications. Her mood
progressively improved, and she was eventually discharged
home.
3. Discussion
The Global Burden of Disease Study projects that, by 2020,
depression will be second only to ischemic heart disease
worldwide as a leading cause of disability-adjusted life years
[4]. Due to this expected increase in prevalence for both
ischemic heart disease and depression and the increasingly
widespread use of ECT, it is essential for physicians to
recognize and manage ECT-related cardiac complications—
the most common adverse eﬀect of ECT.
The variety of cardiac complications of ECT may be
grouped in terms of cardiac ischemia, heart failure, and ar-
rhythmic complications. Ischemic complications reported
include both ST segment and non-ST segment elevation
myocardial infarction [5]. Severe congestive heart failure
resulting from new-onset atrial ﬁbrillation may occur [6].
Arrhythmic complications are by far the most common.
They include minor transient arrhythmias, such as prema-
ture ventricular contractions, but also signiﬁcant tachy-
arrhythmias and bradyarrhythmias, such as atrial ﬂutter,
atrial ﬁbrillation, supraventricular tachycardia, ventricular
tachycardia, new left and right BBBs, 2nd degree AV block,
junctional bradycardia, and asystolic cardiac arrest [5–7].
Routine preoperative evaluation includes a careful history
and physical examination. In the absence of active cardiac
disease (heart failure, arrhythmia, or angina), the only test
recommendedisanECGespeciallyinpatientsabove50years
of age [8].
AV dissociation and complete AV block complicating
ECT has been rarely reported. In 1972, Malik reported com-
plete AV block in a 33-year-old female without any known
medical problems, or any other concurrent medications,
after her 1st ECT session [9]. This patient received premed-
ication with methohexital, succinylcholine, and atropine.
Twenty minutes after the procedure, she was found to be
apneic and in pulseless cardiac arrest. She was resuscitated,
and her ECG revealed complete AV block. Despite emergent
transvenous pacemaker implantation, the patient deterio-
rated into ventricular ﬁbrillation and expired.
The arrhythmic complications of ECT can be easily un-
derstood through the concept of seizure-induced autonomic
nervous system activity. During the early phase of the sei-
zure, parasympathetic activity predominates with a fall in
pulse rate and blood pressure. This is followed by a sympa-
theticallyinducedriseinpulserateandbloodpressure.These
physiological responses can precipitate a variety of cardiac
complications especially in patients with preexisting heart
disease [7]. Bradyarrhythmias are likely to occur when the
parasympathetic activity predominates while tachyarrhyth-
mias are a consequence of unopposed sympathetic activity.
During ECT, periprocedural anesthetics are used to
produce loss of consciousness with minimal convulsive
motor activity. Short-acting agents are generally preferred
given the short duration of seizure activity and the ability to
medicate without intubation. Methohexital for induction of
anesthesia and succinylcholine for neuromuscular blockade
are considered drugs of choice [10]. Both of these agents
were used in our patient and are not known to cause AV
conduction delay.
Anticholinergic therapy with atropine or glycopyrrolate
may be useful in preventing severe bradycardia associated
with the initial parasympathetic response, especially for pa-
tients with pre-existing bradycardia or AV block. There is
ad i ﬀerence of expert opinion regarding the routine use of
anticholinergic agents with ECT [11, 12]. The use of these
medications may not prevent bradyarrhythmias, as shown
in the case reported by Malik, where complete AV block
occurred despite anticholinergic therapy [9].Cardiology Research and Practice 3
Beta-blockers such as labetalol and esmolol are com-
monly used to control sympathetically induced tachycardia
and hypertension associated with ECT. Labetalol, a com-
bined alpha and beta-adrenergic antagonist, is eﬀective
within 5 minutes of administration with a half-life of 4–6
hours. Esmolol is a selective beta-adrenergic antagonist that
iseﬀectivewithin30–90secondsbuthaslittlesustainedactiv-
ityafter10minutes.Althoughesmololisoftenconsideredthe
drug of choice in ECT due to its favorable pharmacokinetic
proﬁle, labetalol continues to be widely used [10].
Drug interactions between psychotropic and cardiac
medications may also predispose to bradyarrhythmias. Ven-
lafaxine and escitalopram, which were used in our patient,
both inhibit the 2D6 isoenzyme of the cytochrome P450
system, thereby decreasing the metabolism of, and resulting
in increased concentrations of metoprolol [13].
The mechanism of AV dissociation in our patient was
multifactorial. The introduction of metoprolol succinate
and more importantly dose escalation before the 8th ECT
session, on a background of structural heart disease and pre-
existing conduction abnormality (RBBB), was her ﬁrst risk
factor for inhibition of AV conduction. Amlodipine, which
was also used, has no signiﬁcant electrophysiological action
on sinus or AV node function in patients receiving beta-
blockers [14]. Psychotropic drug interactions, however,
heightened the intensity of beta-blockade. During ECT, the
initial post-ECT parasympathetic surge combined with the
administration of labetalol worsened AV conduction and
provoked AV dissociation.
AV block due to medication often resolves with the dis-
continuation of the oﬀending agent but frequently recurs,
as illustrated by Zeltser et al. [15]. In their study, 41% of
patients (who were receiving beta-blockers and/or calcium-
channelblockers)convertedtosinusrhythmwithin48hours
after discontinuing the medication. However, 56% of these
patients had recurrence of AV block within the 3 weeks fol-
lowing discontinuation. Zeltseret alconcluded thatwhileAV
block is commonly “related to drugs,” it is rarely “caused by
drugs” and noted that these patients frequently still require
pacemaker implantation. In such cases, the 2008 Guidelines
for Device-Based Therapy of Cardiac Rhythm Abnormalities
from the American College of Cardiology leave this decision
to the purview of the treating physician [16]. They designate
a Class I indication for permanent pacemaker implantation
in asymptomatic persistent third-degree AV block at any
anatomicsitewithaverageawakeventricularratesof40beats
per minute or faster if cardiomegaly or LV dysfunction is
present, or if the site of block is below the AV node.
Inourpatient,continuedbetablockertherapywasneces-
sary to control her hypertension which was not responsive to
twoothermedicationsandastherapyforherstructuralheart
disease. Further sessions of ECT were needed to treat her
depression.Theuseofintravenousbeta-blockerstobluntthe
sympathetic surge associated with ECT would have placed
her in the same milieu that had provoked her episode of
AV dissociation. Pacemaker implantation was thus justiﬁed
based on these indications. The patient received appropriate
preoperative therapy of her hypertension.
4. Conclusion
In summary, we describe the occurrence of AV dissocia-
tion as a complication of ECT. The mechanism involved
patient-related, pharmacologically predisposed, and ECT-
related factors. This case highlights the occurrence of cardiac
bradyarrhythmias with ECT and the need for physicians to
maintain vigilance in detecting and treating these complica-
tions, in order to prevent potentially fatal patient outcomes.
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